Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | TNBC: the targeted therapy era

Adam Brufsky • 2 Jun 2019
ASCO 2019
Breast Cancer

Adam Brufsky, MD, PhD, of the University of Pittsburgh Medical Center. Pittsburgh, PA, tells us about the progress we are seeing in the triple-negative breast cancer (TNBC) field with the rise of targeted agents. Speaking at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL, Dr Brufsky goes on to discuss upcoming trials in the field that he is excited for.

More from Adam Brufsky

2:24
Identifying drivers of first-line HR+/HER2- metastatic breast cancer treatment choices
Adam Brufsky • 6 Dec 2022
1:25
HER2-low as a separate entity for defining HER2 BC and its prognostic and biological significance
Adam Brufsky • 6 Dec 2022
2:58
ImPrint immune signature in 10,000 early-stage breast cancer from the real-world FLEX database
Adam Brufsky • 7 Dec 2022
1:06
SABCS 2022 highlights
Adam Brufsky • 6 Dec 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals